WuXi Biologics: How a Chinese CRDMO Became an Invisible Partner to Half the World's Pharma

WuXi Biologics / 药明生物 operates a model unfamiliar to most of the public but critical to global pharma: CRDMO — Contract Research, Development and Manufacturing Organization. In plain terms, the company develops and manufactures biologic drugs (antibodies, vaccines, complex molecules) on behalf of other pharma companies — from startups to global giants like GSK and BMS — that don't want or can't afford to build in-house manufacturing capacity at that level of complexity. In H1 2026, company revenue grew 18.4% year-on-year to RMB 11.8 billion (23.4% in USD terms).

More than half of clients aren't from China

As of end-June 2026, more than 50% of Research Services programs were sponsored by overseas clients — direct evidence of how deeply the company is embedded in the global drug development chain, rather than just serving the domestic Chinese market. The company supports 50+ active programs eligible for milestone payments and sales royalties — a model that gives WuXi a stake in the commercial success of drugs it helped develop, not just a one-time manufacturing fee.

Complex molecules: the new profit center

A standout growth area is complex biologic modalities — bi- and multi-specific antibodies and antibody-drug conjugates (ADCs): their share exceeded 50% of group revenue in H1 2026, up roughly 30% year-on-year. That's one of modern pharma's most technologically demanding and highest-margin categories, and a Chinese company holding this position is a notable shift — a decade ago, developing such drugs was rarely outsourced to China precisely because of the technical complexity.

Growth outlook and revenue mix

Management expects a compound annual revenue growth rate of 20% over the next three years, with the manufacturing segment expected to be the primary driver at a forecast growth rate of roughly 30% annually. That outlook shows where the company sees the greatest upside: not in development itself, but in scaling its own manufacturing capacity for a growing order book.

What it means for the biotech market

WuXi Biologics illustrates how Chinese companies enter high-tech global markets not through direct competition with established brands, but by embedding themselves in the very infrastructure of drug development — most end consumers will never know their medicine was created or manufactured at a Chinese company's facilities. For the market, that means a growing but largely invisible dependence of the global pharma industry on Chinese manufacturing and research capacity.

Sources

Financial data are drawn from WuXi Biologics' H1 2026 financial results and coverage on BioSpace and PRNewswire.